The popularity of Viagra initially fueled a period of growth for pharma, nevertheless recent shifts present a complicated outlook for shareholders. Off-patent competitors are eroding earnings, and ongoing patent https://phoebelkxb398579.sharebyblog.com/41061667/the-blue-pill-and-big-pharma-a-risky-bet